Evidence map›Paper›PMID 41276415›Full record

ArticleNeuropsychopharmacology reports2025

Possible Involvement of Hallucinogenic Effects in the Aversive Effects Induced by Kappa-Opioid and 5-HT

Hideaki Kato, Yoshimi Ichimaru, Masaaki Kurihara, Koushirou Sogawa, Masahiko Funada, Tsutomu Suzuki

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuropsychopharmacology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. IUCrData · 2026
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hideaki KatoFaculty of Pharmaceutical Sciences, Shonan University of Medical Sciences, Yokohama, Kanagawa, Japan.ORCID https://orcid.org/0009-0005-4537-6639
Yoshimi IchimaruFaculty of Pharmaceutical Sciences, Shonan University of Medical Sciences, Yokohama, Kanagawa, Japan.
Masaaki KuriharaFaculty of Pharmaceutical Sciences, Shonan University of Medical Sciences, Yokohama, Kanagawa, Japan.
Koushirou SogawaFaculty of Pharmaceutical Sciences, Shonan University of Medical Sciences, Yokohama, Kanagawa, Japan.
Masahiko FunadaFaculty of Pharmaceutical Sciences, Shonan University of Medical Sciences, Yokohama, Kanagawa, Japan.
Tsutomu SuzukiFaculty of Pharmaceutical Sciences, Shonan University of Medical Sciences, Yokohama, Kanagawa, Japan.

Funding

Ministry of Health, Labour and Welfare of Japan JPMH22KC1005Ministry of Health, Labour and Welfare of Japan JPMH25KC1002
6 · The paper itself

Abstract

aimThe regulation of new psychoactive and dangerous abused substances is very important for the prevention of drug abuse. A simple and effective evaluation method using laboratory animals is needed to regulate designated drugs with high accuracy and speed.

methodsIn the present study, we used the typical κ-opioid receptor agonist U50,488H and the typical 5-HT

resultsIn the CPA test, both κ-opioid receptor and 5-HT

conclusionTherefore, these tests using mice may be useful for evaluating hallucinogenic effects. We hope that these simple and rapid evaluation methods will be used to identify designated drugs.

Indexed as

3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-IsomerAmphetaminesAvoidance LearningHallucinogensReceptors, Opioid, kappaSerotonin 5-HT2 Receptor AgonistsAnimalsMaleMice3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer4-iodo-2,5-dimethoxyphenylisopropylamineAmphetaminesHallucinogensReceptors, Opioid, kappaSerotonin 5-HT2 Receptor Agonists5‐HT2A/2C receptorconditioned place aversionhallucinogenic drugskappa‐opioid

Identifiers

PMID41276415
PMCPMC12640738

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.